JSPRW — Jasper Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$0.01
+$0.00 (+0.00%)
Jasper Therapeutics Inc (JSPRW) is a biotechnology company listed on NASDAQ. It is led by Ronald A. Martell, based in 2200 Bridge Pkwy, Redwood City, CA, United States, 94065, with about 64 employees. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Net income was -$18.7M.
Use this JSPRW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the JSPRW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the JSPRW SEC filings page. Lician reads the product cache first so this HTML stays unique to Jasper Therapeutics Inc even when a live quote feed is slow.
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
JSPRW Key Statistics
Market Cap
$0.00M
Volume
124,247
Previous Close
$0.01
Day Range
$0.00 – $0.08
EPS
-$4.89
Revenue
$0.00
Net Income
-$71.27M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
64
JSPRW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$71.27M | -$64.47M | $37.70M | $30.60M |
| EPS (Diluted) | -$4.89 | -$6.18 | -$10.33 | -$2.69 |
Total Assets
$79.90M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.64M
Operating Cash Flow
-$62.60M
Free Cash Flow
$0.00
Jasper Therapeutics Inc Company Information
- President, CEO & Director
- Ronald A. Martell
- Headquarters
- 2200 Bridge Pkwy, Redwood City, CA, United States, 94065
- Website
- jaspertx.com
- Phone
- 650 549 1400
- IPO / Founded
- 2020-01-10
- Sector
- Healthcare
- Industry
- Biotechnology